朱彤,刘艳,吴献,姚慧娟,徐阿晶,祁佳,陈霁晖,张健

• 1:上海交通大学医学院附属新华医院临床药学部
• 2:重庆医科大学药学院

摘要(Abstract)：

铁缺乏症是多种疾病的并发症，严重时影响疾病的治疗效果和患者的生存质量及生存期。口服铁剂不耐受或疗效不佳的缺铁患者，建议静脉补铁。蔗糖铁是较早使用的静脉注射铁制剂之一，多年来一系列蔗糖铁类似物也被研发和使用，疗效和安全性等方面各有差异。近年来新型大剂量静脉铁剂的出现也为静脉铁剂的发展提供了新方向。对静脉铁剂及其类似物的药理学特征、临床使用及安全性等进行综述，为静脉铁剂的临床应用提供参考。

关键词(KeyWords)： 静脉注射铁剂;铁缺乏症;缺铁性贫血;补铁治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 朱彤,刘艳,吴献,姚慧娟,徐阿晶,祁佳,陈霁晖,张健

DOI: 10.19577/j.1007-4406.2023.05.015

参考文献(References)：

• [1] DELOUGHERY T G. Iron deficiency anemia[J]. Med Clin North Am, 2017, 101(2):319.
• [2] MACDOUGALL I C, COMIN-COLET J, BREYMANN C, et al.Iron sucrose:a wealth of experience in treating iron deficiency[J].Adv Ther, 2020, 37(5):1960.
• [3] PASRICHA S R, TYE-DIN J, MUCKENTHALER M U, et al. Iron deficiency[J]. Lancet, 2021, 397(10270):233.
• [4]凌寒.我国缺铁性贫血已造成显著疾病负担复旦大学发布中国缺铁性贫血疾病负担和诊疗现状研究成果[J].中国当代医药,2012, 19(32):1.
• [5] GBD DISEASE AND INJURY INCIDENCE AND PREVALENCE COLLABORATORS. Global, regional, and national incidence,prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017,390(10100):1211.
• [6] DELOUGHERY T G. Safety of oral and intravenous iron[J].Acta Haematol, 2019, 142(1):8.
• [7] LEE T, CLAVEL T, SMIRNOV K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD[J]. Gut, 2017, 66(5):863.
• [8] PEYRIN-BIROULET L, WILLIET N, CACOUB P. Guidelines on the diagnosis and treatment of iron deficiency across indications:a systematic review[J]. Am J Clin Nutr, 2015, 102(6):1585.
• [9] BABITT J L, EISENGA M F, HAASE V H, et al. Controversies in optimal anemia management:conclusions from a Kidney Disease:improving Global Outcomes(KDIGO)Conference[J]. Kidney Int, 2021, 99(6):1280.
• [10] DANIELSON B G. Structure, chemistry, and pharmacokinetics of intravenous iron agents[J]. J Am Soc Nephrol, 2004, 15(Suppl 2):93.
• [11] KLEIN K, STOLK P, DE BRUIN M L, et al. The EU regulatory landscape of non-biological complex drugs(NBCDs)follow-on products:observations and recommendations[J]. Eur J Pharm Sci, 2019, 133:228.
• [12] KNOEFF J, FLüHMANN B, MüHLEBACH S. Medication practice in hospitals:are nanosimilars evaluated and substituted correctly?[J]. Eur J Hosp Pharm, 2018, 25(2):79.
• [13]高伟祺,徐娜,宋再伟,等.新型静脉铁剂的安全性：一项系统评价再评价[J].临床药物治疗杂志, 2022, 20(12):7.
• [14]中华医学会血液学分会红细胞（贫血）学组.静脉铁剂应用中国专家共识（2019年版）[J].中华血液学杂志, 2019, 40(5):358.
• [15] GAFTER-GVILI A, SCHECHTER A, ROZEN-ZVI B. Iron deficiency anemia in chronic kidney disease[J]. Acta Haematol,2019, 142(1):44.
• [16]中国医师协会肾脏内科医师分会肾性贫血指南工作组.中国肾性贫血诊治临床实践指南[J].中华医学杂志, 2021, 101(20):1463.
• [17] KLIGER A S, FOLEY R N, GOLDFARB D S, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD[J]. Am J Kidney Dis, 2013, 62(5):849.
• [18]邢婕,张晓良.维持性血液透析患者静脉补铁：对PIVOTAL研究结论的再思考[J].肾脏病与透析肾移植杂志, 2022, 31(3):277.
• [19]中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志, 2018, 34(11):860.
• [20] IQBAL S, EKMEKCIOGLU C. Maternal and neonatal outcomes related to iron supplementation or iron status:a summary of metaanalyses[J]. J Matern Fetal Neonatal Med, 2019, 32(9):1528.
• [21] DIGNASS A U, GASCHE C, BETTENWORTH D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases[J]. J Crohns Colitis,2015, 9(3):211.
• [22]中华医学会消化病学分会炎症性肠病学组.炎症性肠病营养支持治疗专家共识(第二版)[J].中华炎性肠病杂志, 2018, 2(3):154.
• [23]杨欣,李艺,狄文,等.妇科围手术期患者血液管理的专家共识[J].中国妇产科临床杂志, 2019, 20(6):560.
• [24] MU?OZ M, PE?A-ROSAS J P, ROBINSON S, et al. Patient blood management in obstetrics:management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period:NATA consensus statement[J]. Transfus Med, 2018, 28(1):22.
• [25] HAMM R F, BLAUVELT C, WANG E Y, et al. Effectiveness of antepartum intravenous iron sucrose:dose timing and impact on outcomes[J]. J Matern Fetal Neonatal Med, 2021, 34(12):1983.
• [26] KRAFFT A, BENCAIOVA G, BREYMANN C. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone[J]. Fetal Diagn Ther, 2009, 25(2):239.
• [27]中华医学会外科学分会,中华外科杂志编辑委员会.普通外科围手术期缺铁性贫血管理多学科专家共识[J].中华外科杂志,2020, 58(4):252.
• [28] KOZEK-LANGENECKER S A, AHMED A B, AFSHARI A, et al.Management of severe perioperative bleeding:guidelines from the European Society of Anaesthesiology:first update 2016[J]. Eur J Anaesthesiol, 2017, 34(6):332.
• [29] THEUSINGER O M, LEYVRAZ P F, SCHANZ U, et al. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron:efficacy and limits:a prospective study[J]. Anesthesiology,2007, 107(6):923.
• [30]康鹏德,黄强,沈慧,等.中国骨科手术围手术期贫血诊疗指南[J].中华骨与关节外科杂志, 2019(11):833.
• [31] KLIP I T, COMIN-COLET J, VOORS A A, et al. Iron deficiency in chronic heart failure:an international pooled analysis[J]. Am Heart J, 2013, 165(4):575.
• [32] COMíN-COLET J, ENJUANES C, GONZáLEZ G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status[J].Eur J Heart Fail, 2013, 15(10):1164.
• [33] BOLGER A P, BARTLETT F R, PENSTON H S, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure[J]. J Am Coll Cardiol, 2006, 48(6):1225.
• [34] OKONKO D O, GRZESLO A, WITKOWSKI T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF:a randomized, controlled, observerblinded trial[J]. J Am Coll Cardiol, 2008, 51(2):103.
• [35] MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599.
• [36]中国医师协会心力衰竭专业委员会.中国心力衰竭患者离子管理专家共识[J].中华心力衰竭和心肌病杂志, 2020, 4(1):16.
• [37] HEDENUS M, BIRGEG?RD G, N?SMAN P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:a randomized multicenter study[J]. Leukemia, 2007, 21(4):627.
• [38] AUMONT C, DRISS F, LAZURE T, et al. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia[J]. Am J Hematol, 2015, 90(7):131.
• [39]史艳侠,邢镨元,张俊,等.中国肿瘤化疗相关贫血诊治专家共识(2019年版)[J].中国肿瘤临床, 2019, 46(17):869.
• [40] RODGERS G M 3rd, BECKER P S, BLINDER M, et al. Cancerand chemotherapy-induced anemia[J]. J Natl Compr Canc Netw,2012, 10(5):628.
• [41] BEGUIN Y, JASPERS A. Iron sucrose-characteristics, efficacy a n d r e g u l a t o r y a s p e c t s o f a n e s t a b l i s h e d t r e a t m e n t o f i r o n d e f i c i e n c y a n d i r o n-d e f i c i e n c y a n e m i a i n a b r o a d r a n g e o f therapeutic areas[J]. Expert Opin Pharmacother, 2014, 15(14):2087.
• [42] BAILIE G R, CLARK J A, LANE C E, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations[J]. Nephrol Dial Transplant, 2005, 20(7):1443.
• [43] WANG C L, GRAHAM D J, KANE R C, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products[J]. JAMA, 2015, 314(19):2062.
• [44]丁紫嫣,陈且昕,陈力.基于FAERS数据库的静脉铁剂不良事件信号挖掘[J].中国药业, 2022, 31(22):97.
• [45] BLUMENSTEIN I, SHANBHAG S, LANGGUTH P, et al. Newer formulations of intravenous iron:a review of their chemistry and key safety aspects-hypersensitivity, hypophosphatemia, and cardiovascular safety[J]. Expert Opin Drug Saf, 2021, 20(7):757.
• [46] SILVERSTEIN S B, RODGERS G M. Parenteral iron therapy options[J]. Am J Hematol, 2004, 76(1):74.
• [47] ZOU P, TYNER K, RAW A, et al. Physicochemical characterization of iron carbohydrate colloid drug products[J]. AAPS J, 2017,19(5):1359.
• [48] DANIELSON B G, SALMONSON T, DERENDORF H, et al. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers[J].Arzneimittelforschung, 1996, 46(6):615.
• [49] BESHARA S, LUNDQVIST H, SUNDIN J, et al. Pharmacokinetics and red cell utilization of iron(Ⅲ)hydroxide-sucrose complex in anaemic patients:a study using positron emission tomography[J].Br J Haematol, 1999, 104(2):296.
• [50] ASTIER A, BARTON PAI A, BISSIG M, et al. How to select a nanosimilar[J]. Ann N Y Acad Sci, 2017, 1407(1):50.
• [51] FRANCESCO T D, SUBLET E, BORCHARD G. Nanomedicines in clinical practice:are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?[J]. Eur J Pharm Sci,2019, 131:69.
• [52] TOBLLI J E, CAO G, OLIVERI L, et al. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model[J]. Inflamm Allergy Drug Targets, 2012, 11(1):66.
• [53] BORCHARD G, FLüHMANN B, MüHLEBACH S. Nanoparticle iron medicinal products-Requirements for approval of intended c o p i e s o f n o n-b i o l o g i c a l c o m p l e x d r u g s(N B C D)a n d t h e importance of clinical comparative studies[J]. Regul Toxicol Pharmacol, 2012, 64(2):324.
• [54] STEIN J, DIGNASS A, CHOW K U. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator[J]. Curr Med Res Opin, 2012, 28(2):241.
• [55] ZHENG N, SUN D D, ZOU P, et al. Scientific and regulatory considerations for generic complex drug products containing nanomaterials[J]. AAPS J, 2017, 19(3):619.
• [56] SCHELLEKENS H, STEGEMANN S, WEINSTEIN V, et al. How to regulate nonbiological complex drugs(NBCD)and their followon versions:points to consider[J]. AAPS J, 2014, 16(1):15.
• [53]王蔚,王小钦.重视缺铁性贫血的治疗新理念[J].临床内科杂志,2023, 40(1):68.
• [58] AUERBACH M, HENRY D, DERMAN R J, et al. A prospective,multi-center, randomized comparison of iron isomaltoside 1000versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial[J]. Am J Hematol, 2019, 94(9):1007.
• [59] MULDER M B, VAN DEN HOEK H L, BIRNIE E, et al.Comparison of hypersensitivity reactions of intravenous iron:i r o n i s o m a l t o s i d e-1 0 0 0(M o n o f e r?)v e r s u s f e r r i c c a r b o x ymaltose(Ferinject?). A single center, cohort study[J]. Br J Clin Pharmacol, 2019, 85(2):385.
• [60] WOLF M, RUBIN J, ACHEBE M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia:two randomized clinical trials[J].JAMA, 2020, 323(5):432.